Rick Doblin discusses FDA's recent feedback on MDMA-assisted therapy for PTSD, emphasizing transparency and the therapy's potential in clinical practice.
Rick Doblin, PhD
Advertisement
Articles by Rick Doblin, PhD
Advertisement
Latest Updated Articles
MDMA and PTSD, Discussion With Rick Doblin, PhDOctober 6th 2025
Rick Doblin, PhD, Weighs in on the FDA CRL for MDMA-Assisted TherapySeptember 24th 2025
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Should Postpartum Psychosis Be Included in the DSM?
4
Blinding, Ethics, and Safety Safeguards in Psychedelic Clinical Research
5